Phase 3 study was designed to assess the immunogenicity, tolerability and safety of Prevenar 13* in adults between 18 to 49 years of age.
When measure one month succeeding vaccination, Prevenar 13 demonstrated minimum immunogenicity in the study population similar to that observed in adults 60 to 64 years of age.
The vaccine was generally well tolerated and established a safety profile.
Pfizer vaccine clinical research and development senior vice president Dr. William Gruber said, "We continue to further investigate the use of Prevenar 13 with the aim of broadening prevention efforts to additional populations."
With the results, Pfizer expects to seek expansion of the vaccine’s use to include adults 18 to 49 years of age in the European Union, US and other countries across the world.